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1. Introduction 
Intensive research on the neurobiology of pain over the past two decades has revealed many 
receptors, ion channels and enzymes with potential as novel targets for development of a 
new generation of analgesic agents. However, despite large investment in preclinical and 
clinical development of small molecules and biologics as potential novel pain therapeutics, 
very few have reached the clinic. Hence, drugs used in the clinical setting for the 
pharmacological management of pain continue to be those that were first recommended in 
1986 by the World Health Organisation (WHO) for the management of chronic cancer pain 
(WHO, 1986). Twenty-five years on, the WHO 3-step Analgesic Ladder (Figure 1) is still 
used widely to guide the pharmacological management of pain and opioid analgesics are 
the mainstay for alleviation of moderate to severe nociceptive pain.  
 
 
Fig. 1. World Health Organisation 3-Step Analgesic Ladder (WHO, 1986) 
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2. WHO Analgesic Ladder 
The WHO Analgesic Ladder provides a succinct encapsulation of the guidelines for the 
management of chronic pain according to intensity (WHO, 1986). Specifically, for mild 
pain, non-opioid analgesics on Step 1 of the Analgesic Ladder including acetaminophen, 
aspirin and nonsteroidal anti-inflammatory drugs such as ibuprofen, are recommended. 
When the pain has a neuropathic component, addition of an adjuvant agent such as a 
tricyclic antidepressant, anticonvulsant or anti-arrhythmic agent, is recommended. Weak 
opioid analgesics such as codeine, tramadol and dextropropoxyphene are added to  
non-opioid analgesics when mild pain progresses to moderate pain (Step 2); adjuvants  
are again co-administered when the pain has a neuropathic component. Strong opioid 
analgesics are recommended for the management of moderate to severe nociceptive  
pain (Step 3) with morphine the strong opioid analgesic of choice due to its ready 
availability world-wide at low cost. Strong opioid analgesics are often co-administered 
with non-opioids, and adjuvants are added when pain has a neuropathic component 
(WHO, 1986). 
According to the WHO guidelines, each patient should receive a period of individualized 
dose titration on a ‘round the clock’ rather than an ‘as required’ basis as this facilitates 
dosage optimization for the selected analgesic and/or adjuvant (WHO, 1986). Although 
many opioid analgesics have relatively short elimination half-lives (Table 1), most are 
available as sustained-release formulations that are administered once or twice-daily to 
optimize patient compliance as well as pain relief. For patients who experience break-
through pain during ambulation or activities of daily living, additional bolus doses of 
immediate-release formulations are given on an “as required” basis. For most patients, the 
oral dosing route is preferred except where impaired gastrointestinal transit makes this 
impractical as in the immediate post-operative period or during labor.  
3. Opioid analgesics 
Opioid analgesics commonly used for the control of clinical pain include morphine, codeine, 
oxycodone, hydromorphone, buprenorphine, tramadol, fentanyl, remifentanil, pethidine 
and methadone. The potencies of these opioid analgesics differ markedly. Equi-analgesic 
doses and usual starting doses for the oral route derived from the acute pain setting are 
shown in Tables 2 and 3 respectively. 
3.1 Opioid-related adverse effects 
Apart from their desired analgesic action, clinically prescribed opioids also produce many 
undesired effects including respiratory depression, sedation, nausea, vomiting, 
constipation, pruritus, tolerance and dependence, to name but a few (Zollner & Stein, 
2007). Although studies using -opioid (MOP) receptor knockout mice suggest that the 
analgesic and adverse effects of opioid analgesics are all produced by activation of the 
MOP receptor, clinical experience shows that there are marked between-opioid 
differences with respect to analgesic and tolerability profiles within the same patient 
(Smith, 2008). However, the precise mechanistic basis underpinning these observations is 
not well understood.  
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Opioid Analgesic Elimination Half-life (h) 
Duration of Action (h) 
  
Codeine 
Meperidine 
Fentanyl 
Hydromorphone 
Methadone 
Morphine 
Oxycodone 
Tramadol 
Buprenorphine 
3 
3.5 
3.7 
2-3 
24# 
2.5 
3 
5-7 
3 
4-6 
4-6 
0.5-1 (IV); 72 (TD); 2-4 (TM) 
4-5 
4-6 
3-4 
8-12 (CR), 3-4 (IR) 
4-6 (IR), 24 (ER) 
6 
#large inter-individual variability in range 12-150 h 
IV  = intravenous; TD = transdermal; TM = transmucosal 
IR = immediate release; ER = extended release; CR = controlled release 
Table 1. Typical Mean Elimination Half-lives and Durations of Action for Commonly 
Prescribed Opioid Analgesics (adapted from Mather & Smith 1998; Trescot et al., 2008; 
Argoff & Silvershein, 2009)  
 
Opioid Analgesic Dose × Conversion Factor 
Codeine 
Meperidine (IV) 
Methadone 
Oxycodone 
Buprenorphine 
Morphine (IV) 
Morphine (oral) 
x 0.16 
× 0.4 
× 1.5 
× 1.5 
× 50 
× 3 
× 1 
IV = intravenous 
Table 2. Opioid Analgesic Dose Conversion Table to Oral Morphine (adapted from Nissen et 
al., 2011)  
 
Opioid Analgesic 
Oral Administration 
Dose 
Inter-dosing Interval 
(h) 
Codeine 
Fentanyl 
Hydromorphone 
Methadone 
Morphine 
Oxycodone 
Tramadol 
15-60 mg 
100-200 μg (IV) 
2-4 mg 
5-10 mg 
15-30 mg (IR) 
10 mg (CR), 5-10 mg (IR) 
50-100 mg (IR), 100 mg (ER) 
3-6 
6a 
3-4 
24 
4 (IR) 
12 (CR), 4-6 (IR) 
4-6 (IR), 24 (ER) 
CR = controlled-release; ER = extended-release; IR = immediate-release; IV = intravenous;  
aNot more than 4 doses per day. 
Table 3. Common Starting Doses for Selected Opioid Analgesics (adapted from Mather & 
Smith; Argoff & Silvershein, 2009)  
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3.1.1 Respiratory depression 
Opioid-related deaths continue to be reported in the acute pain setting underpinned by 
opioid-induced ventilatory impairment that often develops due to a combination of factors 
including opioid-induced central respiratory depression, sedation and/or upper airway 
obstruction (Macintyre et al., 2011). It is recommended that all patients be monitored for 
opioid-induced ventilatory impairment using sedation scores as a ‘6th vital sign’ so that it 
can be detected early and appropriate intervention initiated (Macintyre et al., 2011). 
3.2 Strategies for minimizing opioid-related adverse effects 
It is essential to assess patients to ensure that adverse effects are genuinely opioid-related 
rather than being due to another medical problem. Strategies recommended (Swegle & 
Logemann, 2006) for minimizing opioid-related adverse effects are as follows: 
1. Titrating opioid doses slowly 
2. Dose reduction to assess if satisfactory analgesia can be obtained with tolerable side-
effects 
3. Symptom management including pro-active preventative treatment of nausea and 
constipation 
4. Addition of, or increasing non-opioid or adjuvant analgesic doses for an opioid sparing 
effect 
5. Opioid rotation  
6. Changing the route of administration 
7. Frequent re-assessment 
3.3 Strategies for managing intolerable opioid-related adverse effects 
For patients experiencing poor pain relief together with intolerable opioid-related side-effects 
such as severe vomiting, severe dysphagia or bowel obstruction, changing from the oral to the 
parenteral (e.g. intravenous, subcutaneous, intramuscular), rectal, buccal, sublingual, 
transdermal or spinal (epidural, intrathecal) route of administration, may reduce adverse 
effects to a tolerable level and restore satisfactory analgesia (Walsh, 2005). Another strategy for 
restoring satisfactory analgesia with tolerable side-effects in such patients is ‘opioid rotation’ 
that involves switching from one strong opioid analgesic to another (Smith, 2008; Knotkova et 
al., 2009; Vissers et al., 2010). Additional clinical strategies for restoring analgesia in patients 
experiencing inadequate pain relief and intolerable opioid-related side-effects include use of 
neurolytic blocks as an adjunct or alternative to pharmacotherapy (Eisenberg et al., 2005) or 
progression to use of anaesthetic intervention if ‘opioid rotation’ fails (Riley et al., 2007). 
3.4 Tolerance to the analgesic effects of opioids 
In the absence of disease progression, tolerance to the analgesic effects of an opioid manifests 
in patients with clinical pain as the need for progressively higher opioid doses in order to 
maintain the same level of pain relief (South & Smith, 2001). In rodent studies, analgesic 
tolerance is demonstrated by a rightward shift in the analgesia dose-response curve for a 
particular opioid administered after a period of chronic dosing relative to the dose-response 
curve determined for the same opioid in opioid-naïve animals (South & Smith, 2001).  
3.5 Tolerance to opioid-related side-effects 
As already noted, opioid-related adverse effects that may occur after the initation of opioid 
analgesic treatment in opioid-naïve patients include respiratory depression, somnolence, 
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nausea, vomiting, miosis, pruritus, constipation, and euphoria/dysphoria. With chronic 
dosing, tolerance often develops to sedation, nausea and respiratory depression whereas 
tolerance to constipation and miosis is minimal (Chang et al., 2007).  
3.6 Opioid analgesics and renal impairment 
Several opioid analgesics including morphine, hydromorphone and meperidine are 
metabolized in the liver to pharmacologically active metabolites that may accumulate in 
patients with renal impairment. Hence, for patients with renal impairment, opioid 
analgesics including oxycodone and fentanyl that are devoid of active metabolites, are 
preferred (King et al., 2011). 
4. Weak opioid analgesics 
4.1 Codeine 
Codeine (7,8-didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol) is an opioid 
alkaloid found in opium, the dried exudate of the unripe seed capsule of the opium poppy, 
Papaver somniferum, at 0.7 to 2.5% (Boerner, 1975). Due to its high consumption rates 
globally, codeine is generally synthesized by O-methylation of morphine, an abundant 
opium constituent at 10-15% (Lenz et al., 1986).  
Codeine is a weak opioid analgesic that binds to the -opioid (MOP) receptor with low 
affinity (Ki = 0.7 M) (Volpe et al., 2011). Its analgesic properties are generally thought to be 
derived from the fact that it is a prodrug for morphine as up to 10% of oral doses are O-
demethylated to morphine by cytochrome P450 2D6 (CYP2D6), an enzyme subject to genetic 
polymorphism (Kadiev et al., 2008, Somogyi et al., 2007, Zollner & Stein, 2007). Supporting 
this notion, plasma morphine concentrations are virtually undetectable and codeine lacks 
efficacy in individuals with the poor metabolizer (PM) CYP2D6 phenotype (Poulsen et al., 
1996). By contrast, codeine is extensively metabolized to morphine in those with the ultra-
metabolizer (UM) phenotype who also have an increased risk of respiratory depression after 
regular doses of codeine (Kirchheiner et al., 2007).  
Doses of codeine generally do not exceed 60 mg (Trescot et al., 2008). Codeine is available in 
a range of prescription and over-the-counter medicines, often in combination with 
paracetamol, aspirin or ibuprofen for pain relief (Moore et al., 1997; Moore et al., 2011). It is 
also the active ingredient in many cough suppressant mixtures and anti-diarrhoeal products 
(Schiller, 1995; Wee, 2008). Codeine is susceptible to metabolic drug-drug interactions with 
other commonly prescribed medications that are also metabolized by CYP2D6 including 
both CYP2D6 inhibitors (e.g. cimetidine) and CYP2D6 inducers (e.g. rifampicin) (Caraco et 
al., 1997; Zhou, 2009).  
4.2 Meperidine (pethidine) 
Meperidine (pethidine; ethyl-1-methyl-4-phenylpiperidine-4-carboxylate), is a synthetic 
MOP receptor agonist that binds with low affinity (Ki = 450 nM) at the MOP receptor (Volpe 
et al., 2011). Meperidine is a weak opioid analgesic with potency at 10% that of morphine 
for the relief of acute post-operative pain (Latta et al., 2002). Meperidine is metabolized by 
hepatic esterases to pethidinic acid, an inactive metabolite, and by N-demethylation to a 
neurotoxic metabolite, normeperidine (Gilman et al., 1980, Armstrong et al., 2009). After 
multiple doses, normeperidine may accumulate in plasma and cerebrospinal fluid causing 
tremors, twitches, myoclonus and seizures as it has a longer plasma half-life than 
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meperidine itself (Plummer et al., 1995; Simopoulos et al., 2002). Meperidine is contra-
indicated in patients with impaired renal function as they are at increased risk of 
normeperidine neurotoxicity due to its faster accumulation (Marinella, 1997; Reutens & 
Stewart-Wynne, 1989). Generally, meperidine use is discouraged in favour of more 
efficacious and less toxic opioid analgesics (Latta et al., 2002). 
4.3 Tramadol 
Tramadol ((1RS,2RS)-2-[(dimethylamino)methyl]- 1 -(3-methoxyphenyl)-cyclo-hexanol 
hydrochloride)  is a synthetic analgesic that is a racaemic mixture of two enantiomers that 
bind to the MOP receptor with low (10 M) affinity (Volpe et al., 2011). After systemic 
administration, tramadol is metabolized in the liver by the enzyme CYP2D6, to its O-
demethylated M1 metabolite, a potent -opioid agonist that contributes to its analgesic 
actions (Subrahmanyam et al., 2001). The (-)-enantiomer of tramadol mainly inhibits 
noradrenaline reuptake in the central nervous system (CNS) to augment descending 
inhibition of pain transmission in the spinal cord whereas the (+)-enantiomer preferentially 
inhibits serotonin reuptake (Reimann & Hennies, 1994). Thus, the pharmacology of 
tramadol is complex with its analgesic action being due to the combined effects of its two 
enantiomers and the M1 metabolite. For this reason, the US Food and Drug Administration 
(FDA) has classified tramadol as a nontraditional, centrally acting analgesic (Grond & 
Sablotzki, 2004).  
For the relief of post-operative pain relief, tramadol is regarded as a “weak” opioid 
analgesic with potency at 10% that of morphine but it does not produce significant 
constipation or respiratory depression and it has low abuse potential (Grond & Sablotzki, 
2004). When tramadol is given in doses larger than the recommended doses, or if it is co-
administered with medications that lower the seizure threshold such as selective serotonin 
reuptake inhibitors, tricyclic antidepressants and antipsychotic drugs, seizures may be 
induced (Gardner et al., 2000). 
5. Strong opioid analgesics 
5.1 Morphine 
Morphine (7,8-didehydro-4,5,-epoxy-17-methyl-(5,6)-morphinan-3,6-diol) is extracted 
from opium due to its relatively high abundance at 10-15% by weight (Boerner, 1975). 
Morphine was first isolated from opium in 1805 by Freidrich Sertűrner, a German 
pharmacist who named it “morphium” after Morpheus the Greek God of Dreams (Milne et 
al., 1996).  
Morphine is the prototypic strong opioid analgesic that binds with high affinity (Ki = 1.2 
nM) at the MOP receptor (Volpe et al., 2011). After oral administration in humans, morphine 
has low oral bioavailability at 20% due to extensive first-pass metabolism in the liver to 
two major metabolites, viz morphine-6-glucuronide (M6G) and morphine-3-glucuronide 
(M3G) that account for 10% and >50% of each dose, respectively (Milne et al., 1996). 
Morphine has a short elimination half-life at 2 h consistent with its short duration of action 
at 4 h (Mather & Smith, 1998). 
M6G, like morphine, binds with high affinity at the MOP receptor and it is a more potent 
analgesic than morphine when given by central routes (Smith & South, 2001). By contrast, 
supraspinally administered M3G evokes dose-dependent neuro-excitatory effects and its 
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actions generally oppose those of morphine in animal studies (Smith, 2000). The elimination 
half-lives of M3G and M6G are in the range 3-4 h (Mather & Smith, 1998). 
After administration of single doses of morphine to patients with clinical pain, the plasma 
and CSF concentrations of M3G exceed those of morphine by several-fold (Hasselström & 
Säwe, 1993) and after chronic dosing, the plasma M3G concentrations exceed the 
corresponding morphine levels by as much as 10-20 fold (Smith et al., 1999). In patients with 
renal impairment, M6G and M3G may accumulate in the plasma and CSF, thereby 
increasing the risk of M6G-induced respiratory depression (Smith & South, 2001) and/or 
M3G-induced neuro-excitation (Smith, 2000). 
Morphine is available in immediate-release and sustained-release oral tablet and capsule 
formulations as well as oral mixtures, rectal suppositories and sterile ampoules for 
parenteral administration by the intramuscular, intravenous, subcutaneous, epidural and 
intrathecal routes (Argoff & Silvershein, 2009). The duration of action for immediate-release 
oral morphine preparations is approximately 3-4 h whereas for oral sustained-released 
morphine tablets and capsules, the duration of action is 12-24 h (Mather & Smith, 1998). The 
convenience of once or twice daily dosing provided by sustained-release formulations 
improves patient compliance and pain relief outcomes (Argoff & Silvershein, 2009).  
5.2 Oxycodone 
Oxycodone ((5-4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one) is a strong 
opioid analgesic that is a semi-synthetic derivative of the abundant opium alkaloid, thebaine 
(Lenz et al., 1986). After oral administration, the bioavailability of oxycodone is high at 60-
87% (Leow et al., 1992; Lalovic et al., 2006). Oxycodone is extensively N-demethylated by 
the enzyme, CYP3A4, to the analgesically inactive metabolite, noroxycodone (Poyhia et al., 
1992; Davis et al., 2003; Lalovic et al., 2004, 2006) with up to another 10% of each dose 
undergoing CYP2D6-catalyzed O-demethylation to the high affinity MOP receptor agonist 
oxymorphone (Lalovic et al., 2006). However, metabolically-derived oxymorphone does not 
contribute significantly to the analgesic actions of oxycodone for the relief of clinical pain 
because its circulating plasma concentrations are very low (1 ng/mL) in both extensive 
metabolisers (EMs) and PMs (0.3 ng/mL) as it is rapidly further metabolized to its 
analgesically-inactive glucuronide conjugate (Lalovic et al., 2006; Zwisler et al., 2010). For 
patients with post-operative pain, there is no difference in analgesic outcomes between PMs 
and EMs (Zwisler et al., 2010), affirming earlier work by others showing that the analgesic 
effects of oxycodone are attributable to the parent opioid alone (Heiskanen et al., 1998; 
Lalovic et al., 1996). 
Radioligand binding studies show that oxycodone has relatively low affinity (Ki = 26 nM) at 
the cloned MOP receptor (Volpe et al., 2011) and that it has a distinctly different binding 
profile from morphine in rat brain homogenate (Nielsen et al., 2007). This likely underpins 
the low extent of cross-tolerance between oxycodone and morphine in rodents (Nielsen et 
al., 2000) and the success of opioid rotation from morphine to oxycodone for the restoration 
of analgesia with tolerable opioid-related side-effects in humans (Narabayashi et al., 2008). 
The potency of intravenous and oral oxycodone for the relief of both post-operative and 
chronic cancer pain is 1.5 times that of morphine (Kalso et al., 1991; Heiskanen & Kalso, 
1997; Bruera et al., 1998). However, when given by the epidural route for the relief of post-
operative pain, the potency of oxycodone is much lower than that of morphine at 11% 
(Backlund et al., 1997).  
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Oxycodone, like morphine, is available in immediate-release and sustained-release tablet 
formulations as well as in oral mixtures, rectal suppositories and ampoules for parenteral 
administration (Argoff & Silvershein, 2009). 
5.3 Methadone 
Methadone, 6-dimethylamino-4,4-diphenyl-heptan-3-one, is a synthetic, strong opioid 
analgesic that is a racaemic mixture of two enantiomers. The analgesic efficacy of 
methadone is multi-faceted as the R-enantiomer is a high affinity MOP receptor agonist  
(Ki = 3.4nM) whereas the S-enantiomer augments descending noradrenergic inhibition to 
block nociceptive signaling in the spinal cord, and both enantiomers have NMDA receptor 
antagonist activity (Davis and Walsh, 2001). 
In humans, methadone has high but unpredictable oral bioavailability at 80% (range  
41-99%) with peak plasma concentrations observed at 2-4 h post-dosing (Trescot et al., 2008; 
Modesto-Lowe et al., 2010). There is a large degree of inter-individual variability in its long 
elimination half-life (12-150 h) (Trescot et al., 2008). These properties make it difficult to use 
for the relief of acute pain or for pain that is poorly controlled where rapid dose adjustments 
are needed (Davis & Walsh, 2001). Further adding to these difficulties, methadone is 
metabolized by CYP3A4-catalyzed N-demethylation to the analgesically inactive metabolite, 
normethadone, such that methadone is potentially subject to a large number of metabolic 
drug-drug interactions as many clinically used drugs are either CYP3A4 inhibitors or 
inducers (Fishman et al., 2002).  
Apart from its use as a strong opioid analgesic for relief of moderate to severe pain, 
methadone is also widely used for opioid maintenance therapy in patients with heroin 
addiction (Fishman et al., 2002). Commercially available methadone formulations include 
oral tablets and mixtures, rectal suppositories and ampoules for parenteral administration 
(Manfredi et al., 2003). When converting patients from a strong opioid analgesic such as 
morphine to methadone, caution needs to be exercised. This is because morphine-
methadone analgesic ratios vary significantly according to the previous morphine dosing 
regimen (Mancini et al., 2000).  
For individuals receiving chronic methadone treatment for opioid dependence, 
cardiotoxicity characterized by prolonged QTc intervals are associated with methadone dose 
and concurrent stimulant use (Modesto-Lowe et al., 2010; Mayet et al., 2011). For individuals 
receiving methadone at doses exceeding 60 mg/day together with tricyclic antidepressants 
or other drugs that inhibit methadone metabolism, the QTc interval is lengthened thereby 
initiating Torsades de Pointes (Krantz et al., 2002, Ehret et al., 2007). QT prolongation with 
methadone is also influenced by other factors including hypokalaemia, hepatic failure and 
pre-existing heart disease (Ehret et al., 2007). Unfortunately, the general lack of awareness of 
the long and highly variable elimination half-life of methadone together with its many 
metabolic drug-drug interactions,  has led to a dramatic increase in methadone-associated 
deaths (Trescot et al., 2008).  
5.4 Hydromorphone 
Hydromorphone, 4,5 alpha-epoxy-3-hydroxy-17-methyl morphinan-6-one, is a semi-
synthetic opioid analgesic (Murray & Hagen, 2005) that binds with high affinity (Ki = 0.37 
nM) at the MOP receptor (Volpe et al., 2011) and to a lesser extent at the -opioid (DOP) 
receptor but not at the -opioid (KOP) receptor (Murray & Hagen, 2005). Orally 
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administered hydromorphone undergoes extensive first-pass metabolism in the liver to 
hydromorphone-3-glucuronide (H3G) that accounts for more than 50% of each dose. 
Although H3G, like M3G, is analgesically inactive, it produces dose-dependent neuro-
excitatory effects after supraspinal administration in rodents with a potency 2.5-fold higher 
than M3G (Wright et al., 2001). Chronic administration of hydromorphone in patients with 
renal impairment will result in H3G accumulation, raising the risk that neuro-excitatory 
side-effects will be produced (Smith, 2000; Mercadante & Arcuri, 2004). 
The analgesic potency of parenteral hydromorphone is  5-fold higher than that of 
morphine for the alleviation of moderate to severe acute pain (Bruera et al., 1996; Dunbar et 
al., 1996; Quigley, 2002; Horn & Nesbit, 2004) whereas for chronic cancer pain, the analgesic 
potency of hydromorphone is similar to that of morphine (Murray & Hagen, 2005). 
Hydromorphone is available as immediate-release and controlled-release oral formulations 
(Guay, 2010) as well as ampoules for parenteral administration by either the epidural or 
intrathecal routes (Lee et al., 2011; Liu et al., 2011). 
5.5 Buprenorphine 
Buprenorphine, ((2S)-2-[(-)-(5R,6R,7R,14S)-9α-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-
hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylbutan-2-ol), is also a semi-synthetic 
derivative of thebaine. Buprenorphine binds with high affinity (Ki = 0.2nM) at the MOP 
receptor (Volpe et al., 2011) and functionally it is a partial agonist (Pick et al., 1997). 
Buprenorphine also has antagonist actions at the -opioid (KOP) receptor and it interacts 
with the nociceptin (ORL-1) receptor (Pick et al., 1997). Buprenorphine produces dose-
dependent analgesia with potency at 25-50 times higher than morphine (Evans & Easthope, 
2003). The slow onset and long duration of buprenorphine’s pharmacodynamic actions are 
thought to be due to its slow binding to and dissociation from the MOP receptor (Evans & 
Easthope, 2003).  
Consistent with its partial agonist activity at the MOP receptor, sublingual buprenorphine 
administered to healthy male volunteers in doses up to 70-fold higher than the 
recommended analgesic dose (0.3 mg) and 4-8 fold higher than doses (4-8 mg) used to treat 
opioid addiction, produced ceiling responses for subjective measures of drug liking in doses 
at 8 to 16 mg (Walsh et al., 1994). In the same subjects a ceiling effect for respiratory 
depression was observed at 16mg (Walsh et al., 1994). Because buprenorphine exhibited 
linear pharmacokinetics across the dose range tested, dose-limited sublingual absorption is 
not responsible for the ceiling effects (Walsh et al., 1994). The KOP antagonist activity of 
buprenorphine is thought to contribute to its good tolerability characterized by limited 
dysphoria or psychotomimetic effects (Johnson et al., 2005).  
After oral administration, buprenorphine undergoes extensive first-pass metabolism in the 
liver catalyzed by the enzymes, CYP3A4 and CYP2C8 to produce the active N-dealkylated 
metabolite, norbuprenorphine (Picard et al., 2005). Consequently the oral bioavailability is 
low at 14% and so buccal, sublingual, intranasal and transdermal formulations of 
buprenorphine have been developed that effectively by-pass first-pass metabolism and 
increase bioavailability to 30-60% (Evans & Easthope, 2003; Johnson et al., 2005; Davis, 2005). 
Due to its long half-life (26 h) and ceiling pharmacodynamic effects, buprenorphine is used 
as an alternative to methadone for opioid maintenance therapy in opioid-dependent 
individuals (Robinson, 2002; Johnson et al., 2005). A combination product containing 
buprenorphine and naloxone in a 4:1 ratio respectively is available in some countries as a 
deterrent to illicit use of buprenorphine tablets for parenteral injection (Harris et al., 2004). 
www.intechopen.com
 
Pain Management – Current Issues and Opinions 
 
296 
5.6 Fentanyl 
Fentanyl, N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenyl-propanamide, is a synthetic opioid 
analgesic (Horn & Nesbit, 2004) that binds with high affinity (Ki = 1.3 nM) at the MOP 
receptor (Volpe et al., 2011). Fentanyl is metabolized by CYP3A4 to its N-dealkylated 
metabolite, norfentanyl that is pharmacologically inactive (Horn & Nesbit, 2004). 
After parenteral dosing, fentanyl is ~80-100 fold more potent than morphine with a rapid 
onset of action but only a short duration at < 60 min (Horn & Nesbit, 2004; Pasero, 2005; 
Stanley, 2005). For post-operative pain relief, fentanyl may be given by spinal routes whereas 
for breakthrough or procedural pain, the sublingual, transmucosal, intra-nasal, inhaled or 
parenteral routes are preferred (Lennernas et al., 2005; Hair et al., 2008; Peng & Sandler, 1999). 
Fentanyl has high lipophilicity making it suitable for transdermal delivery. To this end, 
there are several transdermal patch formulations of fentanyl available for clinical use that 
effectively overcome fentanyl’s short duration of action (Cachia & Ahmedzai, 2011). There is 
now a large body of evidence to support the use of fentanyl patches for the management of 
moderate to severe chronic cancer pain, with data suggesting improved pain relief and 
reduced opioid-related side-effects compared with sustained release oral morphine (Cachia 
& Ahmedzai, 2011). 
5.7 Tapentadol 
Tapentadol, [(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol], is a recently 
approved centrally acting analgesic with two complementary modes of action, viz moderate 
affinity activity at the MOP receptor (Ki = 0.1 M) together with inhibitory effects on the 
NET transporter (Ki = 0.5 M) to block the re-uptake of norepinephrine in the CNS and so 
augment descending inhibition to attenuate pain at the level of the spinal cord (Tzschentke 
et al., 2007; Hartrick, 2009; Wade & Spruill, 2009). After oral dosing, the oral bioavailability 
of tapentadol is relatively low at 32% (Tzschentke et al., 2006) due to significant first-pass 
metabolism in the liver to the inactive glucuronide metabolite, tapentadol-O-glucuronide 
(Terlinden et al., 2010).  
The immediate-release (IR) formulation of tapentadol was approved by the FDA in 2008 for 
the management of moderate-to-severe acute pain as the first new analgesic developed in 
over 25 years (Vadivelu et al., 2011). When compared with oxycodone in a head-to-head 
clinical trial for the relief of post-operative pain in patients following bunionectomy, 
tapentadol provided non-inferior analgesia to oxycodone with a superior gastrointestinal 
adverse effect profile characterized by significantly less nausea, vomiting, and constipation 
when compared with oxycodone (Hartrick, 2009; Vadivelu et al., 2011).  
More recently, the FDA has approved an extended-release (ER) formulation of tapentadol 
for twice-daily oral administration for the management of moderate to severe chronic pain 
in adult patients (Vadivelu et al., 2011). In patients with end-stage joint disease administered 
IR tapentadol for two weeks followed by the ER formulation for a further 4-weeks, the 
superior gastrointestinal tolerability of tapentadol relative to oxycodone, was affirmed 
(Etropolski et al., 2011). Mechanistically, this may be due to an ‘opioid-sparing’ effect of the 
inhibitory actions of tapentadol at the NET transporter (Tzschentke et al., 2006).  
5.8 Ultra-short acting opioid analgesics 
For patients with cardiovascular instability, ultra-short acting structural analogues of 
fentanyl such as remifentanil, alfentanil and sufentanil are preferred for use as part of 
balanced analgesic regimens during anaesthesia (Horn & Nesbit, 2004). 
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5.8.1 Remifentanil 
Remifentanil, 3-[4-methoxycarbonyl-4-[1-oxopropyl)phenylamino]-1-piperidine]propanoic 
acid, methyl ester) is a synthetic derivative of fentanyl with an ester function in its structure 
that makes it susceptible to hydrolysis by non-specific blood and tissue esterases (Egan et 
al., 1993). The very rapid metabolism of remifentanil to the inactive remifentanil acid 
metabolite by non-specific esterases underpins its activity as an ultra-short acting MOP 
agonist (Egan et al., 1993). 
Parenteral remifentanil has a rapid onset of action (~1 min) and a rapid offset of action 
following discontinuation (~3–10 min) (Stroumpos et al., 2010) and it is indicated for the relief 
of pain associated with surgical procedures (Mesolella et al., 2004, Kucukemre et al., 2005). 
Remifentanil’s pharmacokinetics favour its use as an analgesic during labour (Leong et al., 
2011), a notion supported by the findings of two recent clinical studies (Buehner et al., 2011; 
Ng et al., 2011). In the first study, 94% of 244 consecutive women in a small maternity unit 
who received remifentanil by patient-controlled analgesia (PCA) for relief of labour pain 
rated their analgesic outcomes as excellent, very good or good (Buehner et al., 2011). The 
safety profile of remifentanil was also good as the Apgar scores of neonates born to these 
women did not differ significantly from those for neonates born by normal vaginal delivery 
to women who received no analgesia (Buehner et al., 2011). In the second study, maternal 
satisfaction was higher in laboring women who received PCA remifentanil for analgesia 
compared with intramuscular pethidine (Ng et al., 2011) with no difference in the safety 
profile between these two opioid analgesics in the newborn infants (Ng et al., 2011).  
6. Opioid rotation 
For patients experiencing poor pain relief and intolerable opioid-related side-effects on one 
strong opioid analgesic, switching to a second strong opioid analgesic often results in 
restoration of satisfactory pain relief with tolerable opioid-related adverse effects (Knotkova 
et al., 2009; Vissers et al., 2010). The starting dose of the second opioid is selected to 
minimize potential risks whilst ideally restoring analgesic efficacy and must be informed by 
an estimate of its potency relative to the first opioid (Fine et al., 2009; Mercadante & 
Caraceni, 2011). 
Both pharmacokinetic and pharmacodynamic factors may contribute to the clinical success 
of opioid rotation. For opioid analgesics such as morphine and hydromorphone that are 
avidly metabolized to the neuro-excitatory ‘anti-analgesic’ glucuronide metabolites, M3G 
and H3G respectively, opioid rotation facilitates clearance of these metabolites from the 
body enabling restoration of analgesia with the second opioid and resolution of neuro-
excitatory side-effects (Smith, 2000). Additionally, opioid rotation exploits incomplete cross-
tolerance between opioids possibly underpinned by subtle differences in their modulation 
of MOP receptor function (Smith, 2008; Slatkin, 2009).  
7. Peripherally selective opioid antagonists for improving opioid-induced 
constipation 
In patients receiving opioid analgesics for treatment of chronic pain, constipation is a very 
common side-effect that impairs quality of life and has a prevalence of >80% despite 
proactive laxative use (Clemens & Mikus, 2010; Diego et al., 2011). A recent approach to the 
treatment of opioid-induced constipation involves the recent development of quarternary 
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ammonium opioid antagonists such as alvimopan and methylnaltrexone that have limited 
absorption across the gastrointestinal mucosa and do not cross the blood-brain-barrier, as 
well as products that incorporate low-dose oral naloxone that has very low oral 
bioavailability at 2% (Diego et al., 2011). These products selectively target opioid receptors 
in the gastrointestinal tract without affecting centrally-mediated analgesic mechanisms 
(Diego et al., 2011). 
7.1 Alvimopan 
Alvimopan, 2-([(2S)-2-([(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]methyl) -3-
phenylpropanoyl]amino)acetic acid, is an orally active synthetic MOP receptor antagonist 
that is unable to cross the blood-brain-barrier due to the presence of a quaternary 
ammonium group in its chemical structure that is fully ionized at physiological pH (Foss et 
al., 2008; Diego et al., 2011). Thus after oral administration, its actions are confined to 
peripheral sites such as the gastrointestinal tract and it does not reverse centrally mediated 
analgesia (Foss et al., 2008; Karuppiah & Farrah, 2011). Alvimopan has been approved by 
the FDA for short-term use (maximum of 15 doses at twice-daily intervals) in hospitals to 
treat post-operative ileus that may be caused or exacerbated by opioid analgesics (Diego et 
al., 2011). Alvimopan accelerates the time to upper and lower gastrointestinal recovery 
following partial large or small bowel resection with primary anastomosis and decreases the 
time to hospital discharge by approximately one day (Diego et al., 2011; Karuppiah & 
Farrah, 2011).  
The recommended dosing regimen for alvimopan is 12 mg at 0.5-5 h pre-surgery followed 
by 12 mg twice daily for a maximum of 15 doses (Karuppiah & Farrah, 2011). Alvimopan is 
generally well-tolerated when administered for seven days or less (Karuppiah & Farrah, 
2011). However, with long-term use (e.g. 12 months) there is an increased risk of myocardial 
events (Bader et al., 2011; Karuppiah & Farrah, 2011).  
7.2 Methylnaltrexone 
Methylnaltrexone, (5α)-17-(cyclopropylmethyl)-3,14-dihydroxy-17-methyl-4,5-
epoxymorphinanium-17-ium-6-one, is a quaternary ammonium derivative of the opioid 
receptor antagonist, naltrexone (Bader et al., 2011; Diego et al., 2011). Due to the quaternary 
ammonium group in its chemical structure that is ionized at physiological pH, 
methylnaltrexone does not cross the blood-brain-barrier and so centrally mediated analgesia 
is not reversed (Bader et al., Diego et al., 2011).  
Methylnaltrexone has 8-fold and 120-fold higher binding affinity at the MOP receptor 
relative to the KOP and DOP receptors respectively (Bader et al., 2011). Following 
administration by the subcutaneous route at 0.15-5 mg/kg in humans, mean peak plasma 
concentrations of methylnaltrexone are observed at 0.5 h post-dosing and the elimination 
half-life is in the range 8-9 h (Rotshteyn et al., 2011). The mean bioavailability is high at 82% 
with minimal metabolism and so it has low potential for drug-drug interactions (Rotshteyn 
et al., 2011). 
Methylnaltrexone is approved by the FDA and the European Medicines Agency (EMA) to 
treat opioid induced constipation in patients with advanced disease where other laxative 
regimens have failed (Iskedjian et al., 2010; Bader et al., 2011). Methylnaltrexone causes 
laxation in at least 50% of patients in less than 24 h over the first two weeks of treatment 
without impairing analgesia or causing serious adverse events (Bader et al., 2011). 
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7.3 Oral naloxone 
Naloxone, (1S,5R,13R,17S)-10,17-dihydroxy- 4-(prop-2-en-1-yl)-12-oxa-4-azapentacyclo 
[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-one, is a non-selective opioid receptor 
antagonist (Lenz et al., 1986). In the clinical setting, parenteral naloxone is used to reverse 
life-threatening opioid agonist-induced respiratory depression (Diego et al., 2011). However, 
as naloxone crosses the blood-brain-barrier, it also reverses centrally mediated analgesia 
(Diego et al., 2011). 
After oral administration, the bioavailability of naloxone is very low at 2% due to extensive 
first-pass metabolism which makes it possible to obtain a highly localized opioid antagonist 
action in the gastrointestinal tract whilst sparing the centrally mediated opioid analgesic 
effects of oral oxycodone (Leppert, 2010; Diego et al., 2011). The negligible oral 
bioavailability of naloxone is exploited in an oral prolonged-release tablet that contains 
oxycodone in combination with naloxone in a fixed 2:1 ratio resulting in less constipation 
and less laxative consumption relative treatment with oxycodone alone (Leppert, 2010).   
The oxycodone plus naloxone oxycodone tablet is available in four tablet strengths; 5/2.5 
mg, 10/5 mg, 20/10 mg and 40/20 mg oxycodone/naloxone respectively (Leppert, 2010). 
8. Conclusion 
Moderate to severe acute and chronic pain continues to be managed with opioid analgesics 
according to the principles succinctly summarized by Steps 2 and 3 of the WHO 3-step 
Analgesic Ladder. Weak opioid analgesics are added to non-opioid analgesics for the 
management of moderate pain with adjuvants added if pain has a neuropathic component. 
For moderate to severe pain, strong opioid analgesics are recommended with the addition of 
non-opioids and adjuvants, as required.  
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